home / stock / cyccp / cyccp short
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 4,445 |
Total Actual Volume | 19,034 |
Short Trends | |
---|---|
Cover Days | 3 |
Short Days | 16 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 222 |
Average Short Percentage | 82.62% |
Is there a CYCCP Short Squeeze or Breakout about to happen?
See the CYCCP Short Analysis for free Sign up or Login
Powered by Squeeze Report
Stock Date | Open Price | Close Price | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
2022-06-08 | 6.48 | 6.1 | 6.48 | 6.1 | 610 | 540 | 96.4286 |
2022-06-03 | 7.12 | 7.12 | 7.12 | 7.12 | 301 | 79 | 100.0000 |
2022-05-24 | 7 | 7.1 | 7.1 | 7 | 520 | 163 | 100.0000 |
2022-05-10 | 6.48 | 6.48 | 6.48 | 6.48 | 100 | 100 | 100.0000 |
2022-05-09 | 6.48 | 6.48 | 6.48 | 6.48 | 100 | 100 | 100.0000 |
2022-05-06 | 6.48 | 6.48 | 6.48 | 6.48 | 103 | 100 | 100.0000 |
2022-04-28 | 7.15 | 6.35 | 7.15 | 6.35 | 200 | 100 | 100.0000 |
2022-03-29 | 6.7071 | 6.7071 | 6.7071 | 6.7071 | 1,453 | 1,451 | 100.0000 |
2022-01-10 | 7 | 6.97 | 7 | 6.97 | 612 | 300 | 99.6678 |
2021-12-17 | 6.04 | 6.04 | 6.04 | 6.04 | 269 | 10 | 29.4118 |
2021-12-01 | 6.75 | 6.75 | 6.75 | 6.75 | 210 | 150 | 100.0000 |
2021-11-02 | 7.5 | 7.5 | 7.5 | 7.5 | 4,306 | 1 | 100.0000 |
2021-10-26 | 8.0707 | 7.7575 | 8.0707 | 7.4 | 3,110 | 100 | 9.3197 |
2021-10-19 | 8.75 | 7.37 | 8.75 | 7.37 | 961 | 140 | 100.0000 |
2021-09-07 | 8.15 | 8.02 | 8.15 | 8.02 | 897 | 90 | 100.0000 |
2021-09-01 | 8.6 | 9 | 9 | 8.6 | 689 | 5 | 5.2632 |
2021-08-31 | 10.75 | 8.32 | 10.75 | 8.32 | 1,015 | 115 | 46.3710 |
2021-08-16 | 8.4041 | 8.4041 | 8.4041 | 8.4041 | 703 | 700 | 100.0000 |
2021-08-02 | 9.63 | 9.63 | 9.63 | 9.63 | 101 | 1 | 100.0000 |
2021-07-13 | 10.16 | 11 | 11.1667 | 10.16 | 2,774 | 200 | 66.0066 |
Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock Company Name:
CYCCP Stock Symbol:
NASDAQ Market:
News, Short Squeeze, Breakout and More Instantly...
BERKELEY HEIGHTS, N.J., June 22, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Kenneth M....
- Oral Fadraciclib Demonstrating Strong Safety Profile with Continuous Dosing; anticipate entering Phase 2 POC in 2H 2022 - - First Patients Dosed in Phase 1/2 Study of Oral PLK1 Inhibitor CYC140 for Treatment of Advanced Solid Tumors and Lymphomas - - Publicat...
BERKELEY HEIGHTS, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter 2022 financial results on...